Funding of 19.96M SEK to conduct an RCT of Montelukast for treating Parkinson’s disease has been awarded to the group. Link for more information can be found here.
Per Svenningsson elected into the Royal Swedish Academy of Sciences
Link to the news article can be found here
New paper on TAAR1 and SEP-856 published in Neuropsychopharmacology
Our paper peeling back the pharmacology behind the new antipsychotic SEP-856 (Ulotaront) can be accessed here
Per Svenningsson elected as a member of Academia Europaea
Link to Per’s page can be found here
25.05.2022 – PhD defence of Panagiota Tsitsi
13.05.2022 – Mattias Andréasson defends his PhD
Right: Per and Martin Paucar together with thesis opponent Prof. Claudia Trenkwalder
11.05.2022 – Public defence of Ioannis Mantas
Lunch at lab day
Per Svenningsson named as a member of the Molecular Psychiatry Editorial board
Per Svenningsson is now a board member of the editorial team for Molecular Psychiatry. Visit the following link to see all members: https://www.nature.com/mp/editors/editorial-board
Ceremony Arvid Carlsson Foundation award
